B-cell precursor acute lymphoblastic leukemia (ALL) in remission when only a small number of cancer cells remain in the body (minimal residual disease)...read more
B-cell precursor acute lymphoblastic leukemia (ALL) in remission when only a small number of cancer cells remain in the body (minimal residual disease)...read more
If you are in remission, you may still have remaining detectable cancer cells. This is called MRD.1 You should consider being tested for MRD. Ask your doctor if testing is right for you.
BLINCYTO® is the first and only treatment for MRD in ALL.2,3
ALL, acute lymphoblastic leukemia; MRD, minimal residual disease.
What is the most important information I should know about BLINCYTO®?
People with Down Syndrome over the age of 10 years may have a higher risk of seizures with BLINCYTO treatment.
Who should not receive BLINCYTO®?
Before receiving BLINCYTO®, tell your health care provider about all of your medical conditions, including if you or your child:
What should I avoid while receiving BLINCYTO®?
BLINCYTO® may cause serious side effects, including:
The most common side effects
These are not all the possible side effects of BLINCYTO®.
Call your health care provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Please read the accompanying Medication Guide before you or your child receives BLINCYTO® and before each BLINCYTO® infusion and discuss it with your doctor.
Please see BLINCYTO® full Prescribing Information, including BOXED WARNINGS and Medication Guide.
What is the most important information I should know about BLINCYTO®?
References: 1. Brüggemann M, Gökbuget N, Kneba M. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle. Semin Oncol. 2012;39:47-57. 2. BLINCYTO® (blinatumomab) prescribing information, Amgen. 3. Food and Drug Administration. FDA expands approval of Blincyto for treatment of a type of leukemia in patients who have a certain risk factor for relapse. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm603151.htm. Accessed June 18, 2024.